Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Valproic acid (VPA) is commonly used in the treatment of epilepsy due to its broad range of anticonvulsant activity and relative freedom from side-effects. It is also used in the treatment of bipolar affective disorder. Although, its teratogenic effects are well known, the exact mechanism by which it causes these effects is unclear. This review summarises the range of adverse effects that may be seen in Fetal Valproate Syndrome (FVS), the postulated theories for the mechanism of teratogenesis and guidelines for the management of women with epilepsy.

Original publication

DOI

10.1185/146300906X112908

Type

Journal article

Journal

Paediatric and Perinatal Drug Therapy

Publication Date

01/01/2006

Volume

7

Pages

123 - 130